Boston Scientific has received US Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD Fibered Detachable Coil, which is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The first procedure using the device was performed recently at the University of Alabama (Birmingham, USA).
The newest addition to the Boston Scientific interventional oncology portfolio, the EMBOLD Fibered Coil was designed for use in a variety of embolization procedures. A minimally invasive treatment, it is intended to block one or more blood vessels to obstruct or reduce blood flow. Occlusion in this manner is a technique used to stop haemorrhaging, prevent aneurysm ruptures, reduce the size of certain tumours and to treat a variety of venous abnormalities.
“When performing an embolization procedure, it is essential to have a device that is easy to use from start to finish,” explained Theresa Caridi, director of Division of Vascular and Interventional Radiology from the Heersink School of Medicine at the University of Alabama, and the first physician to treat a patient with the EMBOLD Fibered Detachable Coil. “The multicatheter compatibility of the EMBOLD Fibered Coil provides physicians with […] catheter choice and helps reduce the number of potential device exchanges, which may [in turn] improve procedure efficiency and enable better patient outcomes.”
In addition to the multicatheter compatibility of the EMBOLD Fibered Coil, the device also features a nitinol delivery system that prevents kinks from forming in the device during the procedure: this is intended to reduce treatment complications. These design attributes may also reduce preparation and procedure times by limiting the amount of equipment and additional products required to complete treatment, which may reduce the overall cost of the procedure.
